Hugh Nuthall is Executive Director, Search & Evaluation Neuroscience at Eli Lilly and Company, based at Lilly’s European Headquarters near London, UK. The global Search & Evaluation team complements Lilly’s internal Research & Development efforts by evaluating, in-licensing or acquiring assets and technologies and by advancing molecules through discovery and development in collaboration with external partners. Hugh leads Lilly's Search & Evaluation efforts for Neurodegeneration, with a particular interest in Alzheimer’s, Parkinson’s, ALS, and related proteinopathies. Hugh has >25 years’ experience in biomedical research with expertise in pre-clinical disease models, target validation, early drug discovery and translational pharmacology. Hugh has a successful record leading neuroscience drug discovery programs into clinical development and is keenly interested in approaches that modulate the accumulation of misfolded proteins and associated pathological processes in neurodegenerative diseases. Hugh and Lilly Neurodegeneration are also very interested in novel technologies (e.g. CNS delivery), novel modalities (e.g. genetic medicines), and novel biomarkers (e.g. blood-based assays) that could enable and expand Lilly’s research and clinical development pipeline. Prior to Lilly, Hugh worked for Merck at UK and US research sites. Hugh has a DPhil in Molecular Medicine from the University of Oxford, carried out post-doctoral research at the Montreal Neurological Institute, McGill University, and is an author on >30 publications and patents.